Tags » Renal Cell Carcinoma

Life... Too Real

Well, it certainly has been a long time since I’ve posted anything. So much has happened. I thought it had been longer than I thought, I believe my last post was September 2016. 2,163 more words

Exelixis and Takeda strike Japanese R&D deal for cancer therapy cabozantinib

San Francisco-based drug discovery company Exelixis is to collaborate with Japanese pharma giant Takeda in the development of Exelixis’ lead cancer candidate cabozantinib. 

Cabozantinib is a tyrosine kinase inhibitor for both c-Met and VEGFR2 molecules, both of which have been shown to have key roles in tumour growth, metastasis, and angiogenesis (the formation of new blood vessels). 329 more words

Pharma

Disrupting cancer cell communication could prevent tumour growth

Silencing communication pathways between cancer cells could help prevent tumour growth, according to new findings.

The study, carried out by researchers at the Barts Cancer Institute, found that by blocking a molecule called CCR4 – a protein known to be over-expressed in several types of cancer – led to a reduction in tumour growth. 116 more words

Research

White as Snow

After 15 years of dyeing my hair and desperately wanting it to be drastically lighter than my God-given dark brown, borderline-black, natural hair color, the universe finally answered my wish. 838 more words

AYA Cancer

11/9/16 Resident Morning Report - Hemarthrosis, Acquired Factor VIII Inhibitor

CC: 2 days of L knee pain and swelling

ID: 58 yo homeless male with alcohol abuse and seizure disorder presents with 2 days of L knee pain and swelling.   234 more words

Resident Morning Report

Lady Luck

“Bright light city gonna set my soul/Gonna set my soul on fire.” – Elvis Presley, “Viva Las Vegas”

I’ll let you in on a little secret. 1,142 more words

AYA Cancer

Ipsen's and Exelixis' Cabozantinib lowers disease progression and death rate by 31%

Ipsen and its partner Exelixis today announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). 692 more words

News